-
p21 mRNA–LNP Delivery for Bladder Cancer
2026-08-23
The reference study develops an intravesical lipid nanoparticle system for transient delivery of chemically modified CDKN1A/p21 mRNA to bladder tumors. Its evidence links localized p21 restoration with cell-cycle inhibition, DNA-damage accumulation, apoptosis, and tumor suppression in an orthotopic mouse model, while also identifying the limitations that must be addressed before clinical translation.
-
Spiroplasma Entry into S2 Cells: Endocytic Routes
2026-08-22
Wei et al. established a Drosophila Schneider 2 cell model to show that Spiroplasma eriocheiris enters host cells through clathrin-mediated endocytosis and macropinocytosis, with additional dependence on actin filaments and microtubules. The study provides a useful pharmacological framework for dissecting bacterial uptake while highlighting the need to distinguish entry mechanisms from intracellular replication and cell injury.
-
Exo1 for Mechanism-Resolved EV Assays
2026-08-22
Exo1, or methyl 2-(4-fluorobenzamido)benzoate, is a rapid membrane-trafficking perturbation tool for separating Golgi–ER transport effects from extracellular-vesicle biology. This article presents a causal assay framework grounded in recent tumor extracellular-vesicle research, with practical controls and translational limits.
-
PPM-18 for NF-κB and iNOS Research
2026-08-21
PPM-18 offers a practical way to connect NF-κB activation with downstream iNOS expression, nitrite release, and inflammatory phenotypes. This workflow guide covers macrophage assays, sepsis research, bone-inflammation translation, compound handling, and troubleshooting without overstating evidence across model systems.
-
Cabazitaxel (XRP6258): Resistant-Model Guide
2026-08-20
Cabazitaxel (XRP6258, SKU B2157) provides a practical research option for antiproliferative assays involving taxane-resistant or P-glycoprotein-expressing cancer cell lines. It is water-insoluble, so workflows should use DMSO or ethanol, matched vehicle controls, prompt solution use, and carefully documented preparation rather than direct aqueous formulation.
-
Pazopanib Hydrochloride: Reading Drug Response
2026-08-20
Pazopanib Hydrochloride research becomes more informative when growth inhibition and cell death are measured separately. This guide combines GW786034 pharmacology with a decision framework for selecting endpoints, timing experiments, and interpreting anti-cancer assay data.
-
Pyridostatin: A Decision Framework for G4 Assays
2026-08-19
Pyridostatin and Pyridostatin TFA offer a precise way to interrogate G-quadruplex-dependent biology. This article presents a decision framework that separates DNA-based telomere experiments from emerging RNA G-quadruplex and TDP-43 applications.
-
In Vitro Drug Responses: Growth Inhibition and Cell Death
2026-08-19
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability when evaluating anticancer drug responses in vitro. Its central finding is that growth inhibition and cell death commonly occur together but differ in magnitude and timing, making separate endpoint analysis important for cancer research and assay interpretation.
-
Pazopanib Hydrochloride: Reliable Assay Design
2026-08-18
This scenario-driven guide shows how Pazopanib Hydrochloride, SKU A8347, can support more interpretable viability, proliferation, and cytotoxicity experiments. It connects target biology, concentration–time design, readout selection, and practical reagent criteria for cancer research.
-
DPPH Antioxidant Screening: Workflow and Tips
2026-08-18
Use DPPH for fast, plate-compatible ranking of antioxidant capacity in extracts, small molecules, and cultivation samples. This practical workflow combines colorimetric radical scavenging data with orthogonal assays and LC-MS/MS so promising hits can be prioritized without overstating biological relevance.
-
ATS-9R: Designing Adipose Gene-Silencing Studies
2026-08-17
ATS-9R, or Adipocyte-targeting sequence-9-arginine, combines Prohibitin recognition with arginine-rich nucleic acid delivery. This guide translates its GDM and adipose macrophage evidence into practical formulation, control, and assay decisions.
-
Aurora A Overexpression in High-Risk Retinoblastoma
2026-08-17
A 2024 American Journal of Pathology study identifies Aurora kinase A overexpression as a frequent feature of human retinoblastoma and links it with histopathologic factors associated with poor clinical outcomes. By combining patient-tissue analysis with genetic depletion, pharmacologic inhibition, patient-derived models, and xenografts, the study supports AURKA as a functionally relevant target while leaving ocular delivery and clinical efficacy for future investigation.
-
SGC-CBP30 for Super-Enhancer LUAD Research
2026-08-16
SGC-CBP30 provides a selective way to test CREBBP/EP300 bromodomain dependence in transcriptional and chromatin workflows. This guide translates super-enhancer hijacking findings in lung adenocarcinoma into practical dosing, readout, and troubleshooting strategies.
-
M-CSF, Fibrosis, and Translational Macrophage Models
2026-08-15
M-CSF is more than a macrophage culture supplement: it is a controllable biological variable that shapes survival, differentiation, receptor signaling, and downstream inflammatory behavior. This article connects Recombinant Mouse Macrophage Colony Stimulating Factor without Tag to the IGF2BP1/THBS1/TLR4 axis described in pulmonary fibrosis and provides practical strategies for reproducible translational experiments.
-
PNU 74654: Wnt Signaling Workflow Guide
2026-08-14
PNU 74654 is a DMSO-compatible Wnt signaling pathway inhibitor for testing how pathway activity shapes proliferation, differentiation, and progenitor-cell fate. This practical guide connects formulation, assay design, pathway validation, and troubleshooting without treating a pharmacological perturbation as therapeutic proof.